
CLAIMS

1. A use of a riluzole prodrug in the manufacture of a medicament for treating Alzheimer's Disease in a patient in need thereof, wherein said riluzole prodrug has the following formula:



,

or a pharmaceutically acceptable salt thereof.

2. The use of claim 1, wherein the riluzole prodrug is to be administered to the patient at a dosage of from 100 to 400 mg per day.

3. The use of claim 2, wherein the riluzole prodrug is to be administered to the patient at a dosage of 110, or 140, or 150, or 210, or 280, or 350 mg per day.

4. The use of claim 3, wherein the riluzole prodrug is to be administered to the patient at a dosage of 280 mg, once per day.

5. The use of claim 4, wherein the riluzole prodrug is to be administered to the patient at a dosage of 140 mg, twice per day.

6. The use of claim 1, wherein the riluzole prodrug is to be administered to the patient once per day.

7. The use of claim 1, wherein the riluzole prodrug is to be administered to the patient twice per day.


8. The use of claim 1, wherein the riluzole prodrug is to be administered to the patient in the form of a capsule.

9. The use of claim 1, wherein the riluzole prodrug is to be administered to the patient in the form of a tablet.

10. The use of claim 1, wherein the riluzole prodrug is to be administered to the patient for a duration of from 8 weeks to 48 weeks.

11. The use of claim 1, wherein the riluzole prodrug is to be administered to the patient for a duration of from the onset of treatment to the end of the patient's life.

12. A use of a riluzole prodrug in the manufacture of a medicament for improving a response in a patient afflicted with Alzheimer's disease, wherein said riluzole prodrug has the following formula:



,

or a pharmaceutically acceptable salt thereof.

13. The use of claim 12, wherein the improved response is one or more of overall survival, quality of life, overall response rate, duration of response, delay of onset, or patient reported outcome.